Distinct Immune Response in Two MERS-CoV-Infected Patients: Can We Go from Bench to Bedside?
Figure 3
Persistent increased levels of CXCL10 and IL-10 are found in the patient with poor outcome during MERS-CoV infection.
Assessment of CXCL10 and IL-10 protein in sera of the 30 days following MERS-CoV infection in patient 1 (black line) and patient 2 (grey line). (n = 2 to 4, duplicates). Measurement obtained between D0–3: day 0 and day 3, D4–7: day 4 and 7, D8–14: day 8 and 14, D15–21: day 15 and 21, D22–30: day 22 and 30.